MCID: SFT003
MIFTS: 57

Soft Tissue Sarcoma malady

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Soft Tissue Sarcoma

Aliases & Descriptions for Soft Tissue Sarcoma:

Name: Soft Tissue Sarcoma 50 29 41
Sarcoma 69

Classifications:



Summaries for Soft Tissue Sarcoma

NIH Rare Diseases : 50 soft tissue sarcoma is a form of cancer that occurs due to abnormal and uncontrolled cell growth of the "soft tissues" of the body. these tissues connect, support and surround other body parts and may include muscle, fat, blood vessels, lymph vessels, nerves, tendons and the lining of joints. many people with early soft tissue sarcoma have no signs or symptoms of the condition. when present, symptoms depend on the location and size of the tumor but may include a palpable lump under the skin, pain, or difficulty breathing. most cases occur sporadically in people with little to no family history of the condition. people who have previously received radiation therapy and those with certain inherited disorders (such as gorlin syndrome, gardner syndrome, li-fraumeni syndrome, tuberous sclerosis, neurofibromatosis type 1, and werner syndrome) have an increased risk of developing a soft tissue sarcoma. the best treatment options depend on many factors but may include surgery, chemotherapy, and radiation therapy. last updated: 10/17/2016

MalaCards based summary : Soft Tissue Sarcoma, also known as sarcoma, is related to gastrointestinal stromal tumor and rhinosporidiosis. An important gene associated with Soft Tissue Sarcoma is LATS1 (Large Tumor Suppressor Kinase 1), and among its related pathways/superpathways are TGF-Beta Pathway and Cytokine Signaling in Immune system. The drugs Doxorubicin and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include bone, skin and endothelial, and related phenotypes are endocrine/exocrine gland and cardiovascular system

MedlinePlus : 41 your soft tissues connect, support, or surround other tissues. examples include your muscles, tendons, fat, and blood vessels. soft tissue sarcoma is a cancer of these soft tissues. there are many kinds, based on the type of tissue they started in. they may cause a lump or swelling in the soft tissue. sometimes they spread and can press on nerves and organs, causing problems such as pain or trouble breathing. no one knows exactly what causes these cancers. they are not common, but you have a higher risk if you have been exposed to certain chemicals, have had radiation therapy, or have certain genetic diseases. doctors diagnose soft tissue sarcomas with a biopsy. treatments include surgery to remove the tumor, radiation therapy, chemotherapy, or a combination. nih: national cancer institute

Wikipedia : 71 A soft-tissue sarcoma is a form of sarcoma that develops in connective tissue, though the term is... more...

Related Diseases for Soft Tissue Sarcoma

Diseases related to Soft Tissue Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 206)
id Related Disease Score Top Affiliating Genes
1 gastrointestinal stromal tumor 31.7 EGFR MKI67 TP53 VEGFA
2 rhinosporidiosis 28.9 ABCB1 EGFR PIK3CA TP53 VEGFA
3 colorectal cancer 27.4 ABCB1 BCL2 EGFR IFNG MDM2 MKI67
4 soft tissue sarcoma childhood 12.1
5 alveolar soft-part sarcoma 11.8
6 dermatofibrosarcoma protuberans 11.4
7 epithelioid sarcoma 11.3
8 rhabdomyosarcoma 11.3
9 myxoid liposarcoma 11.2
10 embryonal rhabdomyosarcoma 11.2
11 li-fraumeni syndrome 11.2
12 sarcoma, synovial 11.1
13 sarcoma 11.1
14 hemangiopericytoma, malignant 11.0
15 heart malignant hemangiopericytoma 10.8
16 rhabdomyosarcoma, somatic 10.8
17 follicular dendritic cell sarcoma 10.8
18 rhabdoid cancer 10.8
19 rhabdomyosarcoma, embryonal, 2 10.8
20 muscle cancer 10.8
21 rhabdomyosarcoma 2, alveolar 10.8
22 synovium cancer 10.8
23 undifferentiated pleomorphic sarcoma 10.8
24 bednar tumor 10.8
25 rommen mueller sybert syndrome 10.3 MDM2 TP53
26 spondylarthropathy 10.2 MKI67 TP53
27 functionless pituitary adenoma 10.2 MDM2 TP53
28 stocco dos santos syndrome 10.2 IFNG TNF
29 acute mountain sickness 10.2 MDM2 TNF TP53
30 autosomal dominant deafness-onychodystrophy syndrome 10.2 IFNG TNF
31 toxic megacolon 10.2 MDM2 TNF TP53
32 degenerative disc disease 10.2 TNF VEGFA
33 verruciform xanthoma of skin 10.2 PIK3CA TP53
34 enchondromatosis dwarfism deafness 10.2 MDM2 MKI67 TP53
35 paraneoplastic cerebellar degeneration 10.2 MKI67 PIK3CA
36 aortic aneurysm 10.2 MDM2 VEGFA
37 mucopolysaccharidosis 10.1 TNF TP53 VEGFA
38 melanoma 10.1
39 endotheliitis 10.1
40 anterior foramen magnum meningioma 10.1 IFNG TNF TP53
41 gestational choriocarcinoma 10.1 MDM2 TP53 VEGFA
42 distal trisomy 14q 10.1 IFNG TNF
43 mast-cell leukemia 10.1 IFNG TNF TP53
44 uterine ligament clear cell adenocarcinoma 10.1 IFNG TNF TP53
45 twin-to-twin transfusion syndrome 10.1 BCL2 TNF
46 statin toxicity 10.1 BCL2 MKI67 TP53
47 wolffian adnexal neoplasm 10.1 EGFR MKI67 TP53
48 ectodermal dysplasia bartalos type 10.1 IFNG TNF VEGFA
49 liddle syndrome, scnn1g-related 10.1 EGFR VEGFA
50 early myoclonic encephalopathy 10.1 EGFR MDM2 TP53

Graphical network of the top 20 diseases related to Soft Tissue Sarcoma:



Diseases related to Soft Tissue Sarcoma

Symptoms & Phenotypes for Soft Tissue Sarcoma

MGI Mouse Phenotypes related to Soft Tissue Sarcoma:

44 (show all 25)
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.32 VEGFA TP53 EGFR BCL2 ABCB1 TERT
2 cardiovascular system MP:0005385 10.31 VEGFA TP53 EGFR BCL2 ABCB1 PIK3CA
3 growth/size/body region MP:0005378 10.31 VEGFA TP53 ABCB1 EGFR BCL2 TERT
4 cellular MP:0005384 10.3 VEGFA TP53 EGFR BCL2 TNF TERT
5 homeostasis/metabolism MP:0005376 10.29 VEGFA TP53 ABCB1 EGFR BCL2 TNF
6 digestive/alimentary MP:0005381 10.24 VEGFA TP53 EGFR BCL2 ABCB1 TERT
7 immune system MP:0005387 10.24 VEGFA TP53 ABCB1 EGFR BCL2 TNF
8 mortality/aging MP:0010768 10.24 VEGFA TP53 ABCB1 EGFR BCL2 TNF
9 behavior/neurological MP:0005386 10.22 VEGFA TP53 TNF ABCB1 BCL2 PIK3CA
10 hematopoietic system MP:0005397 10.21 TP53 VEGFA ABCB1 EGFR BCL2 TNF
11 integument MP:0010771 10.18 VEGFA TP53 EGFR BCL2 PIK3CA TNF
12 nervous system MP:0003631 10.17 VEGFA TP53 EGFR BCL2 ABCB1 TERT
13 neoplasm MP:0002006 10.16 VEGFA TP53 BCL2 EGFR TERT PIK3CA
14 craniofacial MP:0005382 10.14 VEGFA TP53 EGFR BCL2 TNF IFNG
15 embryo MP:0005380 10.13 TP53 TNF VEGFA EGFR PIK3CA MDM2
16 liver/biliary system MP:0005370 10.11 VEGFA TP53 ABCB1 EGFR TNF LATS1
17 muscle MP:0005369 10.08 VEGFA TP53 EGFR BCL2 TNF PIK3CA
18 no phenotypic analysis MP:0003012 10.06 VEGFA TP53 EGFR ABCB1 PIK3CA TNF
19 adipose tissue MP:0005375 10.02 TP53 TNF BCL2 PIK3CA EGFR
20 reproductive system MP:0005389 10 VEGFA TP53 BCL2 ABCB1 EGFR TERT
21 normal MP:0002873 9.97 VEGFA TP53 EGFR MKI67 TERT LATS1
22 renal/urinary system MP:0005367 9.8 VEGFA TP53 EGFR BCL2 MDM2 IFNG
23 respiratory system MP:0005388 9.7 VEGFA TP53 EGFR BCL2 TNF TERT
24 skeleton MP:0005390 9.56 TP53 VEGFA EGFR PIK3CA TNF TERT
25 vision/eye MP:0005391 9.17 TP53 TNF VEGFA EGFR BCL2 PIK3CA

Drugs & Therapeutics for Soft Tissue Sarcoma

Drugs for Soft Tissue Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 596)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
3
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 155213-67-5 392622
4
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
6
Bleomycin Approved Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
7
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
8
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
9
Lopinavir Approved Phase 4,Phase 2,Phase 3 192725-17-0 92727
10
Nevirapine Approved Phase 4,Phase 3 129618-40-2 4463
11
Tenofovir Approved, Investigational Phase 4,Phase 3 147127-20-6 464205
12
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3 134678-17-4 60825
13
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
14
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 1 154361-50-9 60953
15
Emtricitabine Approved, Investigational Phase 4,Phase 3 143491-57-0 60877
16
Ethiodized oil Approved Phase 4 8008-53-5
17
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
18 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19
protease inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
20 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
21 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
22 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
23 Vaccines Phase 4,Phase 1,Phase 2
24 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Immunoglobulins Phase 4,Phase 3,Phase 1,Phase 2
28 Anti-HIV Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
29 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antibodies, Monoclonal Phase 4,Phase 3,Phase 1,Phase 2
31 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
33 Anti-Retroviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
35 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1
36 Antibodies Phase 4,Phase 3,Phase 1,Phase 2
37 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
40 Lithium carbonate Phase 4 554-13-2
41 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3
42 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1
43 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 2,Phase 3
44 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
45 Tranquilizing Agents Phase 4,Phase 2,Phase 1
46 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4,Phase 3
47 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
48 Antidepressive Agents Phase 4
49 Psychotropic Drugs Phase 4,Phase 2,Phase 1
50 Antimanic Agents Phase 4,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 1602)
id Name Status NCT ID Phase
1 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4
2 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
3 HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT Completed NCT00380770 Phase 4
4 Anti-Retrovirals for Kaposi's Sarcoma Completed NCT00444379 Phase 4
5 OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum. Completed NCT00577031 Phase 4
6 Physical Characteristics of Retrieved Massive Allografts Completed NCT00160758 Phase 4
7 HLA Sensitization Following Major Cortical Allograft Bone Procedures Completed NCT00160719 Phase 4
8 Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer Recruiting NCT02301962 Phase 4
9 Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma Recruiting NCT01669369 Phase 4
10 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
11 Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection Not yet recruiting NCT03144206 Phase 4
12 Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. Not yet recruiting NCT02625389 Phase 4
13 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3
14 An Adequate Cost Effective Follow Up Protocol For Bone & Soft Tissue Sarcomas - A Prospective Randomized Trial Unknown status NCT00384735 Phase 3
15 The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3
16 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3
17 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Unknown status NCT00346164 Phase 3
18 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3
19 A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3
20 Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma Unknown status NCT00379457 Phase 3
21 TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial Unknown status NCT02060006 Phase 3
22 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
23 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Unknown status NCT00954174 Phase 3
24 Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor Unknown status NCT00685828 Phase 3
25 Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor Unknown status NCT00103168 Phase 3
26 A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma Unknown status NCT02099396 Phase 2, Phase 3
27 Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma Unknown status NCT00691236 Phase 2, Phase 3
28 A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Completed NCT01440088 Phase 3
29 Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma Completed NCT00142571 Phase 3
30 Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed NCT00753688 Phase 3
31 Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Completed NCT02049905 Phase 3
32 Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma Completed NCT01168791 Phase 3
33 Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma Completed NCT01327885 Phase 3
34 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3
35 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3
36 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3
37 A Prospective Randomized Trial of Pre-Operative IMRT+Surgery Versus Surgery Alone For Primary Retroperitoneal Sarcoma Completed NCT00131898 Phase 3
38 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
39 A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma Completed NCT00001300 Phase 3
40 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
41 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
42 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3
43 Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor Completed NCT00006734 Phase 3
44 A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies Completed NCT00699517 Phase 3
45 Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002985 Phase 3
46 Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) Completed NCT00538239 Phase 3
47 An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS) Completed NCT00796120 Phase 3
48 A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002319 Phase 3
49 Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. Completed NCT00002147 Phase 3
50 Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma Completed NCT00003350 Phase 3

Search NIH Clinical Center for Soft Tissue Sarcoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Soft Tissue Sarcoma

Genetic tests related to Soft Tissue Sarcoma:

id Genetic test Affiliating Genes
1 Soft Tissue Sarcoma 29

Anatomical Context for Soft Tissue Sarcoma

MalaCards organs/tissues related to Soft Tissue Sarcoma:

39
Bone, Skin, Endothelial, Neutrophil, Breast, Lung, Brain

Publications for Soft Tissue Sarcoma

Articles related to Soft Tissue Sarcoma:

(show top 50) (show all 995)
id Title Authors Year
1
Surveillance Imaging Patterns and Outcomes Following Radiation Therapy and Radical Resection for Localized Extremity and Trunk Soft Tissue Sarcoma. ( 28058559 )
2017
2
Treatment of soft tissue sarcoma: a focus on earlier stages. ( 27918202 )
2017
3
Curcumin and Viscum album Extract Decrease Proliferation and Cell Viability of Soft-Tissue Sarcoma Cells: An In Vitro Analysis of Eight Cell Lines Using Real-Time Monitoring and Colorimetric Assays. ( 28045549 )
2017
4
Dramatic Reduction in Tumor Size During 5 Months of Pazopanib Therapy in Combination With Ifosfamide, Carboplatin, and Etoposide in an Early Infant With Progressive Soft Tissue Sarcoma. ( 28067691 )
2017
5
The importance of treating by histological subtype in advanced soft tissue sarcoma. ( 27918201 )
2017
6
Antia89proliferative activity of epigallocatechina893a89gallate and silibinin on soft tissue sarcoma cells. ( 27909727 )
2017
7
Evolution in soft tissue sarcoma. ( 27918200 )
2017
8
Cost-Effectiveness Analysis of Preoperative Versus Postoperative Radiation Therapy in Extremity Soft Tissue Sarcoma. ( 28068242 )
2017
9
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. ( 27621408 )
2016
10
In brief: Two Drugs for soft-tissue sarcoma. ( 27148925 )
2016
11
Evaluation of minimal disseminated disease in cryopreserved ovarian tissue from bone and soft tissue sarcoma patients. ( 27591237 )
2016
12
Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma. ( 27561088 )
2016
13
Potential pitfalls of mass spectrometry to uncover mutations in childhood soft tissue sarcoma: A report from the Children's Oncology Group. ( 27642091 )
2016
14
Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients. ( 27622032 )
2016
15
Epigenetic regulation of SMARCB1 By miR-206, -381 and -671-5p is evident in a variety of SMARCB1 immunonegative soft tissue sarcomas, while miR-765 appears specific for epithelioid sarcoma. A miRNA study of 223 soft tissue sarcomas. ( 27223121 )
2016
16
Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy. ( 27208537 )
2016
17
Radiation Therapy for Soft Tissue Sarcoma: Indications and Controversies for Neoadjuvant Therapy, Adjuvant Therapy, Intraoperative Radiation Therapy, and Brachytherapy. ( 27591502 )
2016
18
Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. ( 26897615 )
2016
19
TERT promoter mutations in soft tissue sarcomas. ( 26391479 )
2016
20
Chondroitin sulfate synthase 1 expression is associated with malignant potential of soft tissue sarcomas with myxoid substance. ( 26997434 )
2016
21
Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma. ( 27069131 )
2016
22
Radiologic Response Assessment in Pediatric Soft Tissue Sarcoma: Computed-Assisted Volume Evaluation. ( 27939125 )
2016
23
Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin. ( 27574465 )
2016
24
The width of resection margins influences local recurrence in soft tissue sarcoma patients. ( 27107792 )
2016
25
SU-G-JeP4-14: Assessment of Inter- and Intra-Fractional Motion for Extremity Soft Tissue Sarcoma Patients by Using In-House Real-Time Optical Image-Based Monitoring System. ( 28047555 )
2016
26
A pilot trial of doxorubicin containing phosphatidyldiglycerol based thermosensitive liposomes in spontaneous feline soft tissue sarcoma. ( 27592502 )
2016
27
Epigenetic re-expression of HIF-2I+ suppresses soft tissue sarcoma growth. ( 26837714 )
2016
28
Prospective evaluation of Ki-67 system in histological grading of soft tissue sarcomas in the Japan Clinical Oncology Group Study JCOG0304. ( 27091124 )
2016
29
Prognostic Significance of Apoptosis-related Markers in Patients With Soft-Tissue Sarcomas of Extremities. ( 25906122 )
2016
30
Adipose-induced Retroperitoneal Soft Tissue Sarcoma (RSTS) Tumorigenesis: A Potential Crosstalk between Sarcoma and Fat Cells. ( 27621268 )
2016
31
Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum. ( 27566012 )
2016
32
Health-related quality of life following treatment for extremity soft tissue sarcoma. ( 27634326 )
2016
33
Prognosis value of Hypoxia-inducible factor-1I+ expression in patients with bone and soft tissue sarcoma: a meta-analysis. ( 27606158 )
2016
34
Fatal hemorrhage in a patient with advanced soft tissue sarcoma following radiation and pazopanib treatment: A case report. ( 27073488 )
2016
35
Progress for Soft Tissue Sarcoma. ( 27997639 )
2016
36
Role of isolated limb perfusion with recombinant human tumor necrosis factor I+ and melphalan in locally advanced extremity soft tissue sarcoma. ( 27197621 )
2016
37
Paediatric and adult soft tissue sarcomas with NTRK1 gene fusions: a subset of spindle cell sarcomas unified by a prominent myopericytic/haemangiopericytic pattern. ( 26863915 )
2016
38
Extended resection including adjacent organs and Ki-67 labeling index are prognostic factors in patients with retroperitoneal soft tissue sarcomas. ( 26911364 )
2016
39
Individual and Combined Expression of DNA Damage Response Molecules PARP1, I^H2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients. ( 27643881 )
2016
40
PROLONGED FEVER WITHOUT OBVIOUS ETIOLOGY FINALLY DIAGNOSED AS HIGH-GRADE SOFT TISSUE SARCOMA. ( 27125079 )
2016
41
Raf Kinase Inhibitor Protein Expression and Prognostic Value in Soft Tissue Sarcomas. ( 26859895 )
2016
42
Early detection of local recurrence after soft tissue sarcoma resection and flap reconstruction. ( 27184055 )
2016
43
Older Age Modifies Oncologic Outcome Following Radiotherapy in Soft-tissue Sarcoma: A Subtype-specific SEER Analysis. ( 27069154 )
2016
44
Soft tissue sarcoma in the dog - part 1: a current review. ( 27624929 )
2016
45
Cardiac dysfunction among soft tissue sarcoma patients in Denmark. ( 27186077 )
2016
46
Implications of staged reconstruction and adjuvant brachytherapy in the treatment of recurrent soft tissue sarcoma. ( 27180128 )
2016
47
Evaluation of Soft Tissue Sarcoma Response to Preoperative Chemoradiotherapy Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging. ( 28066805 )
2016
48
Positron emission tomography (18)F-fluorodeoxyglucose uptake and prognosis in patients with bone and soft tissue sarcoma: A meta-analysis. ( 27189833 )
2016
49
Outcome of extracranial malignant rhabdoid tumours in children registered in the European Paediatric Soft Tissue Sarcoma Study Group Non-Rhabdomyosarcoma Soft Tissue Sarcoma 2005 Study-EpSSG NRSTS 2005. ( 27082136 )
2016
50
Primary retroperitoneal soft tissue sarcoma: Imaging appearances, pitfalls and diagnostic algorithm. ( 28057392 )
2016

Variations for Soft Tissue Sarcoma

Cosmic variations for Soft Tissue Sarcoma:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM575 NRAS soft tissue,skin,sarcoma,NS c.38G>C p.G13A 13

Expression for Soft Tissue Sarcoma

Search GEO for disease gene expression data for Soft Tissue Sarcoma.

Pathways for Soft Tissue Sarcoma

Pathways related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.48 BCL2 EGFR IFNG PIK3CA TNF TP53
2
Show member pathways
13.3 BCL2 EGFR IFNG PIK3CA TNF TP53
3
Show member pathways
12.97 BCL2 EGFR MDM2 PIK3CA TP53 VEGFA
4
Show member pathways
12.87 BCL2 IFNG PIK3CA TNF TP53
5
Show member pathways
12.78 BCL2 MDM2 PIK3CA TNF TP53
6
Show member pathways
12.69 EGFR MDM2 PIK3CA TP53
7
Show member pathways
12.63 EGFR IFNG TNF TP53
8 12.57 BCL2 EGFR MDM2 PIK3CA TP53 VEGFA
9
Show member pathways
12.52 EGFR MDM2 PIK3CA TP53
10
Show member pathways
12.48 EGFR PIK3CA TNF TP53
11 12.47 LATS1 MDM2 MKI67 TP53
12 12.44 BCL2 EGFR MDM2 PIK3CA TP53 VEGFA
13
Show member pathways
12.41 BCL2 EGFR IFNG PIK3CA TNF TP53
14 12.4 PIK3CA TERT TNF TP53
15
Show member pathways
12.38 BCL2 EGFR MDM2 PIK3CA TP53
16
Show member pathways
12.3 BCL2 EGFR MDM2 PIK3CA TP53
17
Show member pathways
12.29 EGFR MDM2 PIK3CA TP53
18 12.22 BCL2 IFNG MDM2 PIK3CA TP53
19 12.18 ABCB1 BCL2 EGFR MDM2 PIK3CA TP53
20
Show member pathways
12.09 EGFR MDM2 PIK3CA
21 12.09 BCL2 MDM2 PIK3CA TP53
22 12.09 EGFR IFNG TNF TP53 VEGFA
23
Show member pathways
12.06 EGFR MDM2 PIK3CA
24 12.04 BCL2 MDM2 TP53
25
Show member pathways
12.04 BCL2 IFNG PIK3CA
26 12.04 BCL2 EGFR MDM2 TP53
27 12.04 EGFR PIK3CA TNF TP53
28 12.04 BCL2 EGFR MDM2 TP53 VEGFA
29 12.04 EGFR MDM2 PIK3CA TNF TP53 VEGFA
30 12.02 IFNG PIK3CA TNF
31
Show member pathways
12 EGFR PIK3CA TP53
32 11.99 EGFR IFNG TNF TP53
33 11.98 BCL2 PIK3CA TNF TP53
34 11.97 MDM2 PIK3CA TP53
35
Show member pathways
11.96 BCL2 TNF TP53
36 11.96 BCL2 MDM2 PIK3CA TP53
37 11.95 BCL2 TNF TP53 VEGFA
38 11.94 EGFR MDM2 TP53
39
Show member pathways
11.93 EGFR MDM2 PIK3CA
40 11.91 BCL2 IFNG MDM2 TP53
41
Show member pathways
11.91 EGFR MDM2 PIK3CA TP53 VEGFA
42 11.87 IFNG PIK3CA TNF
43 11.86 BCL2 PIK3CA TNF VEGFA
44 11.84 IFNG TNF VEGFA
45 11.81 BCL2 PIK3CA TP53
46 11.79 IFNG MDM2 TP53
47 11.72 BCL2 EGFR IFNG PIK3CA VEGFA
48
Show member pathways
11.7 BCL2 PIK3CA TERT
49 11.7 EGFR MDM2 TP53 VEGFA
50 11.69 EGFR IFNG TERT

GO Terms for Soft Tissue Sarcoma

Biological processes related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

(show all 38)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.97 BCL2 EGFR IFNG MDM2 VEGFA
2 cell proliferation GO:0008283 9.94 BCL2 EGFR MKI67 TP53
3 positive regulation of apoptotic process GO:0043065 9.92 IFNG LATS1 TNF TP53
4 response to drug GO:0042493 9.9 ABCB1 BCL2 IFNG MDM2
5 negative regulation of neuron apoptotic process GO:0043524 9.84 BCL2 PIK3CA TERT
6 negative regulation of gene expression GO:0010629 9.84 IFNG MDM2 TERT TNF
7 positive regulation of gene expression GO:0010628 9.83 IFNG MDM2 TNF TP53 VEGFA
8 phosphatidylinositol-mediated signaling GO:0048015 9.81 EGFR PIK3CA TP53
9 positive regulation of protein phosphorylation GO:0001934 9.78 EGFR IFNG TNF VEGFA
10 positive regulation of MAP kinase activity GO:0043406 9.75 EGFR TNF VEGFA
11 humoral immune response GO:0006959 9.73 BCL2 IFNG TNF
12 negative regulation of apoptotic process GO:0043066 9.73 BCL2 EGFR MDM2 TERT TP53 VEGFA
13 positive regulation of cell adhesion GO:0045785 9.72 IFNG TNF VEGFA
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.7 EGFR IFNG TNF
15 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.68 EGFR TNF
16 positive regulation of osteoclast differentiation GO:0045672 9.67 IFNG TNF
17 positive regulation of pri-miRNA transcription from RNA polymerase II promoter GO:1902895 9.67 TERT TP53
18 positive regulation of protein export from nucleus GO:0046827 9.67 MDM2 TP53
19 response to iron ion GO:0010039 9.66 BCL2 MDM2
20 negative regulation of growth of symbiont in host GO:0044130 9.65 IFNG TNF
21 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.65 IFNG TNF
22 negative regulation of anoikis GO:2000811 9.65 BCL2 PIK3CA
23 digestive tract morphogenesis GO:0048546 9.64 BCL2 EGFR
24 growth GO:0040007 9.63 BCL2 VEGFA
25 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.63 BCL2 TERT TNF
26 replicative senescence GO:0090399 9.61 TERT TP53
27 regulation of mitochondrial membrane permeability GO:0046902 9.61 BCL2 TP53
28 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.59 MDM2 TERT
29 positive regulation of chemokine biosynthetic process GO:0045080 9.58 IFNG TNF
30 negative regulation of mitotic cell cycle GO:0045930 9.54 BCL2 EGFR TNF
31 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.51 IFNG TNF
32 positive regulation of protein complex assembly GO:0031334 9.5 IFNG TNF VEGFA
33 cellular response to actinomycin D GO:0072717 9.49 MDM2 TP53
34 positive regulation of vitamin D biosynthetic process GO:0060557 9.4 IFNG TNF
35 cellular response to hypoxia GO:0071456 9.35 BCL2 MDM2 TERT TP53 VEGFA
36 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.33 MDM2 TERT TNF
37 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.02 BCL2 LATS1 PIK3CA TNF VEGFA
38 negative regulation of transcription from RNA polymerase II promoter GO:0000122 10.02 IFNG MDM2 TNF TP53 VEGFA

Molecular functions related to Soft Tissue Sarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.8 ABCB1 EGFR LATS1 MKI67 PIK3CA TP53
2 ubiquitin protein ligase binding GO:0031625 9.46 BCL2 EGFR MDM2 TP53
3 protease binding GO:0002020 9.43 BCL2 TNF TP53
4 protein phosphatase binding GO:0019903 9.13 BCL2 EGFR TP53
5 identical protein binding GO:0042802 9.1 BCL2 EGFR MDM2 TNF TP53 VEGFA

Sources for Soft Tissue Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....